Naoko Ida
Matsuoka, 9101193, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Acute leukemia therapy at a crossroads: from conventional chemotherapy to the era of precision medicine.
Journal: Biochemical pharmacology
Published: May 07, 2026
Targeting drug efflux and DNA repair enhances inotuzumab ozogamicin activity in IO-resistant B-ALL cell lines.
Journal: International journal of hematology
Published: September 19, 2025
Adult-onset Vitamin K-dependent Coagulation Factor Deficiency of Unidentified Etiology.
Journal: Internal medicine (Tokyo, Japan)
Published: September 10, 2025
Adult-onset Vitamin K-dependent Coagulation Factor Deficiency of Unidentified Etiology.
Journal: Internal medicine (Tokyo, Japan)
Published: September 10, 2025
Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: August 27, 2024
Combining inotuzumab ozogamicin with PARP inhibitors olaparib and talazoparib exerts synergistic cytotoxicity in acute lymphoblastic leukemia by inhibiting DNA strand break repair.
Journal: Oncology reports
Published: January 13, 2024
Lineage switch from T-lymphoblastic leukemia to myeloid leukemia at relapse
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: August 05, 2021
The clinical significance of CD49e and CD56 for multiple myeloma in the novel agents era.
Journal: Medical oncology (Northwood, London, England)
Published: May 27, 2020
Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: A Report of Four Cases.
Journal: Internal medicine (Tokyo, Japan)
Published: May 12, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026